







7 THYROID 8 CARCINOMA

Frontiers in Diagnosis and Management

SEPTEMBER, 12-13TH 2014 Auditorium Centro Congressi Frentani Via dei Frentani, 4 - Rome

WWW.ROMATIROIDE.IT





Frontiers in Diagnosis and Management

PROGRAM

15.40-16.00

16.00-16.10

Friday - September 12, 2014

13.50-14.20	Registration
14.20-14.30	Introduction and remarks R. Bellantone, S. Filetti, A. Pontecorvi
14.30-15.20	SATELLITE SYMPOSIUM - L-Thyroxine replacement therapy Presiding: <i>M. D'Armiento, F. Trimarchi</i>
14.30-14.50	L-Thyroxine therapy in hypothyroidism: unmet needs <i>B. Biondi</i>
14.50-15.10	L-Thyroxine absorption and new L-Thyroxine formulations <i>M. Centanni</i>
15.10-15.20	Discussion
15.20-16.10	I SESSION - Symposium: Thyroid nodules Presiding: E. Papini, R. Vigneri
15.20-15.40	Cytological classification SIAPEC AIT: Italian proposal 2014 <i>G. Fadda</i>

The Natural History of Benign Thyroid Nodules

16.10-18.00 II SESSION - Clinical Case Seminar

Discussion with the audience

C. Durante

Low Risk Differentiated Thyroid Cancer. Total thyroidectomy vs lobectomy: searching for an optimal approach

Presiding: R. Bellantone, D. Cooper

Case presentation: P. Locantore

Panel: G. Giugliano, C. Lombardi, F. Pacini, A. Pontecorvi, J.A. Sosa

Content: Starting from a case presentation, the panel will address the following issues:

- What is the appropriate diagnostic and surgical approach for indeterminate thyroid nodules?

- What is the appropriate surgical approach for patients with small (but greater than 1 cm), intra-thyroid, unifocal papillary carcinoma in the absence of sonographic evidence of cervical lymph node involvement?
- What if there is contralateral benign nodular disease?

What do the 2014 American Thyroid Association guidelines say? B. Haugen

Discussion with the audience

Saturday - September 13, 2014

09.00-09.30 III SESSION - Lecture

Presiding: A. Giustina, P. Vitti

Increased incidence of thyroid nodules and thyroid cancers: an epidemic of diagnosis or an epidemic of disease? - S. Franceschi

09.30-11.30 IV SESSION - Clinical case seminar

New Paradigms in the Treatment and in the Follow-up of Differentiated Thyroid Cancer Patients: Radioiodine Therapy and Long-Term Follow up

Presiding: D. Cooper, P. Miccoli

Case presentation: L. Lamartina

Panel: S. Corsello, C. De Crea, S. Filetti, M. Raffaelli,

M. Salvatori, M. Tuttle

Content: Starting from a case presentation, the panel will address the following issues:

- Is there a role for prophylactic central neck dissection?
- How to estimate the post-operative risk of persistent/recurrent disease? How to estimate the risk of death?
- Which patients should undergo RAI remnant ablation? What are the risk from RAI therapy? What activity of 131I should be used? What is the role of recombinant human TSH in preparation of patients to RAI treatment?
- Which diagnostic tools should be used to monitor differentiated thyroid cancer patients after the initial treatment?
- Which patients can be considered "cured"? How and how long should they be followed?

What do the 2014 American Thyroid Association guidelines say? B. Haugen

Discussion with the audience

11.30-12.00 V SESSION - Thyroid disease networks

Presiding: M. Attard, E. Puxeddu

C.A.P.E.: The endocrine patients network - A. Biancifiori, E. Bonfanti P. Polano

Familial DTC thyroid cancer registry - C. Durante

12.00-12.30 VI SESSION - The Aldo Pinchera Lectureship Award Endowed by Fondazione "Umberto Di Mario" Onlus and by unrestricted grant from IBSA, to honor the memory of Aldo Pinchera. The award is conferred upon an outstanding investigator who has made major contribution in thyroid oncology research.

Presiding: A. Lenzi, P. Vitti

12.30-14.00 Lunch

14.00-16.00 VII SESSION - Symposium: Local and systemic therapies for the management of advanced thyroid carcinoma Presiding: G. De Toma, M. Schlumberger

- 14.00-14.20 Neck reoperation for persistent/recurrent thyroid carcinoma: the case of differentiated and medullary thyroid carcinoma *J.A. Sosa*
- 14.20-14.40 Sorafenib and Lenvatinib: results from phase III randomized trials in patients with metastatic radioactive iodine-refractory differentiated thyroid cancer L. Locati
- 14.40-15.00 Vandetanib and Cabozantinib: opening a new treatment practice in advanced medullary thyroid carcinoma R. Elisei
- 15.00-15.20 Tyrosine kinase inhibitors therapy: adverse events, management strategies and supportive therapies E. Cortesi
- 15.20-15.40 Next generation clinical trials for thyroid cancer S. Sherman
- 15.40-16.00 Discussion with the audience
- 16.00-16.15 Closing remarks



VENUE

Auditorium - Centro Congressi Frentani Via dei Frentani 4, Rome

OBJECTIVES OF THE COURSE

The course was designed with the objective to provide an update on the most recent areas of research with regard to the diagnosis, follow-up and treatment of thyroid cancer, both in the forms of low risk and high risk of mortality. A special focus is dedicated to the discussion of topics with controversy issues lacking of clinical recommendations based on findings from international clinical guidelines.

PROMOTER

Sapienza Università di Roma Università Cattolica del Sacro Cuore Fondazione Umberto di Mario Onlus

AUDIENCE

- Specialists in Endocrinology, Oncology, Internal medicine, Nuclear Medicine and Endocrine Surgery, Pathologist, Cytologist
- Pharmacologists
- Doctors in training, fellows

ORGANIZING COMMITTEE

- S. Filetti
- R. Bellantone
- A. Pontecorvi

SCIENTIFIC COMMITTEE

- R. Bellantone
- D. Cooper
- G. De Toma
- S. Filetti
- C. Lombardi
- A. Pontecorvi

SEGRETERIA ORGANIZZATIVA

FASI s.r.l.
Via R. Venuti 73
00162 Roma
Tel. 06 97605611
Fax 06 97605650
I.capriotti@fasiweb.com
www.fasiweb.com
E V E N T I

